Dr. Subir Basak

Dr. Subir Basak has had an exciting career spanning 24 years in US and India, wherein he has been involved as CEO, Board Member, and Business Head overseeing Sales and Marketing, Business Development, R&D, Quality, Manufacturing and Strategy. He is currently on a sabbatical and serves as a Management Consultant working with Biotech and pharma companies.

He spent nine months, from March-November 2015 as the Senior Vice President and Global Head of Business Excellence at Biocon. From 2012-2015, Dr. Basak was the President and Board member of Jubilant Biosys and Chemsys and Managing Director of Vanthys (Eli-Lilly-Jubilant JV) managing 3 R&D and Manufacturing sites in US and India. From 2010-2012, he served as the Chief Commercial Officer of Intas Biotech, where he leveraged his general management skills to consolidate the Intas Biotech business, wherein R&D, Manufacturing, and Commercial operations worked under his supervision. His team was involved in the successful dossier submission and approval for India's first biosimilar to the European Union and many emerging markets. Beforehand, he was the Global Head of Oncology & Specialty Business at Dr Reddys wherein he focused on building a strong Specialty focus and pipeline. He was inspired by the 'Make in India' concept and migrated to India in 2005, where he started the Onco-Therapeutics BU at Biocon which won the Biospectrum Award for BIOMAB and also licensed Abraxane for SAARC and MENA. Dr. Basak has held senior management positions at the US Headquarters of Amgen, Bayer and Merck, where he was instrumental in leading the development and commercialization of Biotech products and Sales & Marketing of in-line blockbuster products such as Neupogen and Neulasta.

Dr. Basak has a B.E. in Chemical Engineering from Indian Institute of Technology (IIT Roorkee), MS & PhD in Biochemical Engineering from Purdue University, USA, and Kellogg MBA from Northwestern University, USA & Advanced Management Education from the Wharton School of Business, USA. He has been profiled in a Harvard Business Review case study related to Innovation, Biotechnology, and Emerging markets. He is a Member of the Healthcare Executive Advisory Board, USA, TIE Charter Member, India, and Member of the National Committee of Biotechnology of the Confederation of Indian Industry (CII).